Slump In Generic Submissions Helps US FDA Draw Nearly Even With Approvals
Agency Publishes Data For First Half Of Current Fiscal Year
Executive Summary
ANDA approval rates have remained steady, while submission rates dropped compared to prior years.
You may also be interested in...
FDA Guides On Virtual Inspections During COVID-19
Details of how the FDA plans to conduct remote evaluations of manufacturing facilities during the COVID-19 pandemic have been set out in guidance published by the US agency.
Remote Site Visits Will Help US FDA Keep Reviews On Track During Remainder Of Pandemic
Video facility tours expected to help clear way for timely drug and biologic approvals while COVID-19 still prevents inspections.
ANDA Sponsors Could Lose Exclusivity Because COVID-19 Prevented An Inspection … Or Not
US FDA will determine on a case-by-case basis whether its inability to inspect a facility because of the pandemic could result in 180-day exclusivity forfeiture for first generic filers.